CUSIP: 45845PAB4
What is CUSIP 45845PAB4?
CUSIP 45845PAB4 identifies 45845PAB4 - INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 in SEC 13F datasets.
Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.
Open recent reporting periods for CUSIP 45845PAB4:
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2024 Q1 | $0 | $0 | -$2,973,750 | 0 | |
| 2023 Q4 | $3,000,000 | $2,973,750 | -$88,145,889 | 99.13% | 1 |
| 2023 Q3 | $69,639,076 | $91,099,758 | +$27,093,668 | 98.35% | 13 |
| 2023 Q2 | $56,641,230 | $64,964,565 | +$4,016,734 | 80.42% | 9 |
| 2023 Q1 | $39,846,230 | $49,702,186 | +$828,852 | 83.13% | 7 |
| 2022 Q4 | $48,143,730 | $56,762,308 | +$3,818,716 | 75.69% | 7 |
| 2022 Q3 | $34,845,230 | $40,683,000 | +$953,379 | 75.54% | 7 |
| 2022 Q2 | $45,270,795 | $35,952,000 | -$9,897,045 | 65.04% | 6 |
| 2022 Q1 | $71,851,000 | $43,610,000 | 60.42% | 7 | |
| 2021 Q4 | $71,851,000 | $43,423,000 | -$1,441,320 | 60.42% | 7 |
| 2021 Q3 | $74,460,000 | $44,636,000 | -$74,758,902 | 60.16% | 6 |
| 2021 Q2 | $193,553,000 | $130,150,000 | -$14,145,812 | 66.71% | 11 |
| 2021 Q1 | $225,406,985 | $147,093,568 | -$2,310,677 | 64.82% | 18 |
| 2020 Q4 | $224,162,000 | $135,668,461 | -$2,969,434 | 60.04% | 19 |
| 2020 Q3 | $231,137,000 | $160,765,883 | -$8,640,181 | 69.3% | 22 |
| 2020 Q2 | $221,011,000 | $164,675,388 | -$3,542,538 | 72.23% | 33 |
| 2020 Q1 | $225,688,000 | $198,155,243 | +$18,038,736 | 86.9% | 33 |
| 2019 Q4 | $195,783,000 | $261,969,568 | +$2,145,178 | 132.68% | 30 |
| 2019 Q3 | $203,580,000 | $184,150,602 | -$9,711,513 | 90.37% | 29 |
| 2019 Q2 | $211,575,000 | $219,686,524 | +$217,942,000 | 99.45% | 27 |